Inari Medical ( (NARI) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Inari Medical’s stock saw a significant rise after the announcement that Stryker Corporation plans to acquire the company for $80 per share in cash, valuing the deal at about $4.9 billion. This news prompted various analysts to adjust their price targets and ratings. While firms like Wells Fargo, Canaccord, and Deutsche Bank downgraded the stock, aligning their price targets with the acquisition offer due to the premium price suggesting limited further upside, Piper Sandler raised its target, highlighting the strategic fit with Stryker’s neuro franchise. The overall analyst sentiment is cautious, acknowledging both the strategic advantages and the high price of the offer, along with potential integration challenges.
More about Inari Medical
YTD Price Performance: 25.48%
Average Trading Volume: 1,140,675
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.81B
For further insights into NARI stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.